Results 121 to 130 of about 7,686 (201)

The efficacy of preoperative evolocumab-rosuvastatin combination therapy in patients with ST-elevation myocardial infarction. [PDF]

PLoS One
Li H, Dong H, Bao S, Wang X, Fu Z.
europepmc   +1 more source

Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial. [PDF]

Front Neurol
Liu J, Han C, Ji X, Cao H, Chen S, Tan C, Hao X, Joyama Y, Zou W, Li Y, Liu J.   +10 more
europepmc   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source

A szérum lipidszintet csökkentő szerek hazai felhasználásának változása 2007–2015 közötti periódusban az OEP adatbázisa alapján = Change in use of serum lipid lowering agents between 2007-2015 based on NHI data [PDF]

, 2017
Barna, István, Gyurcsányi, András
core   +1 more source

PCSK9 Promotes Platelet Activation and NET Formation, Aggravating Pulmonary Microthrombosis in Sepsis-Induced Lung Injury. [PDF]

Biomedicines
Lv X, Xiong W, Jiang L.
europepmc   +1 more source

PCSK9 inhibitors: a promising lipid-lowering strategy for kidney transplant recipients. [PDF]

Ren Fail
Luo B, Guo L, Di W.
europepmc   +1 more source

Effects of PCSK9 inhibitor evolocumab on preventing early neurological deterioration in acute ischemic stroke patients with or without large artery atherosclerosis: a subgroup analysis of a randomized trial. [PDF]

BMC Neurol
Liu J, Li Y, Tian W, Cao H, Li X, Cheng L, Ji X, Liu J.   +7 more
europepmc   +1 more source

Efficacy and Safety of Evolocumab in Improving Low-Density Lipoprotein Cholesterol (LDL-C) Levels in a Japanese Population　- Systematic Review and Meta-Analysis. [PDF]

Circ Rep
Sheng F, Miyawaki K, Osada N, Tanaka S, Liu Z, Shinke T.   +5 more
europepmc   +1 more source

Insights from Patients and Physicians About Use of Evolocumab for LDL-C Management. [PDF]

Adv Ther
Sidelnikov E, Jones LK, Debrosse A, Okorozo P, Kalich B.   +4 more
europepmc   +1 more source

Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis. [PDF]

Front Pharmacol
Niu Q, Wang Q, Chen F, Li B.
europepmc   +1 more source